Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North America.
The choice of dopaminergic therapy in early Parkinson disease (PD) is an important clinical decision, yet factors influencing this decision have not been extensively studied. We sought to investigate the factors that may be associated with the choice of dopaminergic therapy at the NINDS Exploratory Trials in PD (NET-PD) Long-Term Study-1 (LS1). NET-PD LS1 was a clinical trial of creatine versus placebo in participants with early, mild PD on stable doses of dopaminergic therapy. Baseline data from 1616 out of the 1741 participants were evaluated using univariable and multivariable logistic or generalized logit regression analyses for available factors associated with the choice of dopaminergic therapy. The dopaminergic therapy choice was determined as: (i) therapy that subjects recalled taking 180days before the study; (ii) therapy at baseline; and (iii) the longest duration of therapy reported by participants. Younger age, higher education level, longer length of time since PD diagnosis and use of an adjunctive, non-dopaminergic or monoamine oxidase inhibitor medication were associated with more frequent use of dopamine agonist compared to levodopa or combination therapy.
Department of Neurology, Michigan State University, 804 Service Rd Room A217, East Lansing, MI 48824, USA. Electronic address: john.goudreau@hc.msu.edu.
John L
JL
Goudreau
Department of Biostatistics, The University of Texas Health Science Center at Houston, UTHealth, USA. Electronic address: adriana.perez@uth.tmc.edu.
Adriana
A
Pérez
Department of Neurology, University of California San Francisco, 505 Parnassus Ave, Moffitt, San Francisco, CA 94143, USA. Electronic address: Michael.Aminoff@ucsf.edu.
Michael J
MJ
Aminoff
Department of Neurological Sciences, University of Vermont, College of Medicine, 1 So. Prospect Street, UHC - Arnold 2, Burlington, VT 05401, USA. Electronic address: James.Boyd@uvm.edu.
James T
JT
Boyd
Department of Biostatistics, The University of Texas Health Science Center at Houston, UTHealth, USA. Electronic address: kb_athome@yahoo.com.
Keith D
KD
Burau
Department of Neurology, University of California San Francisco, 505 Parnassus Ave, Moffitt, San Francisco, CA 94143, USA. Electronic address: chad.christine@ucsf.edu.
Chadwick W
CW
Christine
Department of Neurology, University of Colorado, School of Medicine, Academic Office 1, Mail Stop B-185, 12631 East 17th Avenue, Aurora, CO 80045, USA. Electronic address: maureen.leehey@ucdenver.edu.
Maureen
M
Leehey
Department of Neurology, Georgia Regent's University, 1120 15th St, Augusta, GA 30912, USA. Electronic address: jmorgan@gru.edu.
John C
JC
Morgan
D000367:Age Factors; D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D002170:Canada / Q000453:epidemiology; D002755:Choice Behavior; D015259:Dopamine Agents / Q000627:therapeutic use*; D004522:Educational Status; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D015999:Multivariate Analysis; D010300:Parkinson Disease / Q000188:drug therapy* / Q000453:epidemiology*; D010342:Patient Acceptance of Health Care / Q000706:statistics & numerical data*; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
D000978:Antiparkinson Agents; D015259:Dopamine Agents; D008996:Monoamine Oxidase Inhibitors
Clinical trial; Dopamine agonists; Levodopa